1976
A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors
Robinson R, DeVita V, Levy H, Baron S, Hubbard S, Levine A. A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors. Journal Of The National Cancer Institute 1976, 57: 599-602. PMID: 978771, DOI: 10.1093/jnci/57.3.599.Peer-Reviewed Original ResearchConceptsSolid tumorsSerum glutamic oxaloacetic transaminaseSerum glutamic pyruvic transaminaseSeparate drug trialsObjective tumor responseDetectable serum levelsRoute of administrationChronic myelogenous leukemiaLow serum concentrationsGlutamic oxaloacetic transaminaseGlutamic pyruvic transaminasePolyriboinosinic-polyribocytidylic acidPoly I-poly CInducers of interferonCoagulation abnormalitiesSerum levelsMultiple dosesSerum concentrationsTumor responseAcute leukemiaDrug trialsBlast crisisMyelogenous leukemiaTransient elevationDrug dose
1973
Streptozotocin for Malignant Insulinomas and Carcinoid Tumor: Report of Eight Cases and Review of the Literature
Schein P, Kahn R, Gorden P, Wells S, DeVita V. Streptozotocin for Malignant Insulinomas and Carcinoid Tumor: Report of Eight Cases and Review of the Literature. JAMA Internal Medicine 1973, 132: 555-561. DOI: 10.1001/archinte.1973.03650100069013.Peer-Reviewed Original ResearchMalignant insulinomaBone marrow depressionDrug dose levelsPeak serum concentrationComplete remissionMarrow depressionMetastatic insulinomaObjective responseCarcinoid tumorsMalignant carcinoidSerum concentrationsInfusion rateLow doseStreptozotocinDose levelsInjection sitePatientsInsulinomaLimited responseRemissionCarcinoidsResponseChemotherapyPainTumors